| Discipline | Oncology |
|---|---|
| Language | English |
| Edited by | Mels Sluyser |
| Publication details | |
| History | 1990–present |
| Publisher | |
| Frequency | 10/year |
| 1.784 (2014) | |
| Standard abbreviations ISO 4 (alt) · Bluebook (alt) NLM (alt) · MathSciNet (alt  ) | |
| ISO 4 | Anti-Cancer Drugs |
| Indexing CODEN (alt · alt2) · JSTOR (alt) · LCCN (alt) MIAR · NLM (alt) · Scopus · W&L | |
| ISSN | 0959-4973 (print) 1473-5741 (web) |
| Links | |
Anti-Cancer Drugs is an internationalmedical journal, which aims to promote and encourage research onanti-cancer agents. It was first published in 1990 and it includes reports on clinical and experimental research results, from conventional cytotoxicchemotherapy to hormonal or biological response modalities.[1] The journal has 10 issues per year and the currenteditor in chief is Mels Sluyser. According to the 2014Journal Citation Reports, the journal has animpact factor of 1.784, ranking it 164th out of 211 in the category Oncology and 162nd out of 254 in the category Pharmacology & Pharmacy.
  | This article about anoncologyjournal is astub. You can help Wikipedia byexpanding it. See tips for writing articles about academic journals. Further suggestions might be found on the article'stalk page. |